4
Changes in Ownership
Trevi Therapeutics, Inc. Filed Acc 0001209191-23-024115
Chief Financial Officer sold 840 shares at $1.84 ($1,545)
- Chief Financial Officer acquired 2,292 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Delfini Lisa Chief Financial Officer | 2023-04-11 | Option exercise 10b5-1 | +2,292 | $0.51 | $1,171 | 27,029 | D |
| Delfini Lisa Chief Financial Officer | 2023-04-11 | Sale 10b5-1 | −840 | $1.84 | $1,545 | 26,189 | D |
| Derivatives | |||||||
| Delfini Lisa Chief Financial Officer | 2023-04-11 | Option exercise · Stock Option (right to buy) 10b5-1 | −2,292 | 77,917 | D | ||
| Open-market sales · 840 sh · avg $1.84 · $1,545 | |||||||
Loading xslF345X04/doc4.xml…